Models · Choosing one
Which Peptide Business Should You Actually Build?
Research peptide brands and telehealth companies share a market and some of the same molecules. Commercially, they are different companies, and knowing which one you are building can save a new founder from building the wrong one.
Before we start. This article reflects our operating experience and research as of September 2026. It is provided for general educational purposes and does not constitute legal, regulatory, medical or financial advice. Healthcare, pharmacy, telehealth and research-product requirements vary by product, activity and jurisdiction. Retabionix figures represent our own historical business performance and are not typical or guaranteed results.
When people first look at the peptide market, everything tends to blur together.
You see research peptide companies selling products online. You see GLP-1 telehealth brands advertising weight-management programs. You see pharmacies, laboratories, wholesalers, clinics and suppliers. Some of the same names (semaglutide, tirzepatide and various peptides) appear across completely different websites.
From the outside, it can look like everyone is in roughly the same business, but they are not.
This became much clearer to us the deeper we got into the industry. A research-focused peptide ecommerce business and a telehealth company that helps patients access prescription medication run on different models. They have different customers, different revenue mechanics, different infrastructure and very different responsibilities.
If we were putting our own money into this market today, we’d want to know which game we were playing before we spent a dollar on it.
Start With the Simplest Distinction
A genuine research-product business is a commerce business. A telehealth business is a healthcare delivery business with a commerce layer around it.
Model one
Research product
A commerce business.
- Customer
- Store
- Product
- Payment
- Fulfillment
Model two
Telehealth
A healthcare delivery business.
- Patient
- Intake
- Provider
- Clinical decision
- Prescriptionif medically appropriate
- Pharmacy
- Medication
- Ongoing care
That difference shapes almost everything downstream. In the first model you are designing a product company. In the second you are coordinating a healthcare experience.
So skip the question of which market is hotter.
Ask which machine you want to own.
Once you answer that, most of the confusion clears.
Telehealth Is Not “Selling Peptides Online”
This is probably the biggest misconception we run into.
Imagine somebody launches a telehealth weight-management company. A patient arrives because they’re interested in treatment. They complete an intake. A qualified healthcare provider evaluates them. If treatment is medically appropriate, the provider may prescribe a medication. A pharmacy dispenses it, and there may then be ongoing clinical care.
The entrepreneur isn’t supposed to be sitting behind the website deciding who gets tirzepatide.
- The clinician makes clinical decisions.
- The pharmacy performs the pharmacy function.
- The telehealth company coordinates the experience around those regulated functions.
That split creates complexity and opportunity. A well-built telehealth company can make convenient something that used to mean calling a doctor’s office, waiting for an appointment, traveling to a clinic, visiting a pharmacy and coordinating several parties. Technology can shorten that process.
That is why telehealth can be a strong business model. It also means you are building infrastructure around healthcare, which is a bigger job than ecommerce.
The Patient’s Location Matters
In the United States, this is where telehealth gets complicated. A founder might assume that if the consultation happens online, geography should not matter.
It does, because healthcare licensure is still largely state-based. HHS explains that the ability to deliver health care services across state lines varies by state. Depending on the circumstances, providers may need a full state license, qualify through reciprocity or a licensure compact, use a temporary-practice provision, or register under a state’s telehealth pathway.
A website reaches every state. A medical license does not automatically follow it.
A physician sitting in Florida having a video consultation with someone physically located in another state can bring the rules of the patient’s state into play. That is a different scaling problem from shipping.
A research ecommerce company asks “can we ship there?” A telehealth company also has to ask “can our clinical network appropriately serve a patient there?”
When a telehealth company advertises nationwide access, there may be substantial clinical and licensing infrastructure behind those two words. For an entrepreneur, that shows where part of the moat can come from.
Telehealth Is a Network Business
From the outside, a telehealth company looks like a website. A strong one can be a network connecting patients, technology, licensed providers, pharmacy infrastructure, medication fulfillment and the ongoing patient experience.
Much of the value sits in the coordination rather than in any single piece. The customer sees one brand. Behind it may sit a whole set of partners, carrying much greater regulatory and clinical responsibility than an ordinary marketplace.
A Research Peptide Brand Is a Different Kind of Opportunity
Compare that with a legitimate research-focused product company. The business is much closer to specialized ecommerce and distribution. You’re thinking about product selection, supply, appropriate analytical testing, documentation, packaging, inventory, branding, commerce, payments, fulfillment, customer service, B2B accounts and customer acquisition.
The core economic unit will be familiar to anyone who has run ecommerce. You acquire a customer, they buy, and you earn gross margin. Some customers buy again, some buy several products, and you may also develop wholesale or B2B relationships.
So the machine becomes products, distribution, brand, repeat purchasing and B2B. That is close to the model we built with Retabionix, and commercially there is a lot we like about it. We went through how those pieces fit together, and how a single infrastructure layer can serve more than one revenue stream, in Why a Supplier and a Website Aren’t Enough.
The Owner Doesn’t Need to Build a Healthcare Organization
This matters if you are weighing both models. If you are building a genuine research-product company, you are building a product business. You are not trying to create a nationwide network of clinicians to prescribe your research products to consumers.
That does not make it regulation-free, and the distinction has to be real, not something that lives only in a footer disclaimer. FDA has been active here in 2026.
In a warning letter issued to Royal Peptides LLC on 24 August, FDA wrote:
“Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or animal consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a ‘peptide guide’ and ‘peptide calculator,’ resources that collectively provide the means to prepare an injectable drug for human administration.” US Food and Drug Administration, 24 August 2026
FDA made a similar determination involving Gram Peptides earlier this year.
Putting “research use only” on the bottle does not finish the job. We work from a simpler rule.
Build the company you claim to operate.
If you’re operating a research-focused business, its positioning, products, content, customer journey and marketing should all be consistent with that model, built with appropriate professional guidance. That holds up better than asking one disclaimer to carry the whole company.
The Revenue Engines Are Different Too
Imagine two companies each doing $500,000 per month. The dashboards might show the same number while the businesses underneath have little in common.
A telehealth company’s economics may include patient acquisition, provider costs, pharmacy relationships, technology, patient support, prescription-related workflows and potentially recurring membership or care-program revenue. A research ecommerce business might instead have product costs, testing, packaging, warehousing, payment fees, fulfillment, customer acquisition and support.
Revenue tells you how much money passed through the front door. It doesn’t tell you what kind of house is behind it.
Telehealth Has an Attractive Feature Ecommerce Founders Notice Immediately
That feature is recurring revenue. A telehealth program may involve an ongoing patient relationship rather than a one-off transaction. When appropriate treatment continues over time, the business may have recurring economics around that relationship. Commercially that is attractive, because customer acquisition is easier to justify when the relationship has meaningful lifetime value.
Recurring revenue does not appear because you put “$299/month” on a pricing page. You have to earn retention. Patients need appropriate ongoing care, and the provider network, pharmacy fulfillment, customer service and the economics all have to work.
Medical appropriateness comes before commercial retention
Here healthcare differs from ordinary subscription ecommerce. Netflix is happy if you stay subscribed forever. A healthcare company cannot approach clinical decisions on the assumption that keeping every patient on every treatment indefinitely is the commercial objective.
Clinical decisions have to rest on clinical grounds, separate from the revenue plan.
Research Ecommerce Creates Recurring Economics a Different Way
A product company does not need a formal subscription to build repeat revenue. Repeat purchasing can come from customer behavior on its own. That is one reason we watch cohorts, not just first-order revenue.
Two advertising campaigns, six months apart
Campaign A
Campaign B
The more expensive customer may have been the cheaper one.
On the first order, Campaign A wins. By month six, the answer has flipped. That is why experienced ecommerce operators stop comparing cost per acquisition only with first-order revenue and start comparing it with contribution margin over the customer lifetime.
It is a better way to run growth, and once you have enough transaction history you can make those calls with your own data instead of industry guesses.
One Business Is More Clinical. One Is More Commercial.
Side by side, the difference looks like this.
Both take serious execution, but they reward different founder strengths. Someone from ecommerce, branding, distribution or direct response may pick up the second machine faster. Someone with healthcare infrastructure, provider relationships or clinical operations experience may find the first a more natural fit.
The GLP-1 Boom Made the Difference Easier to Miss
There is a historical reason people confuse these businesses. When GLP-1 demand surged, consumers started seeing semaglutide and tirzepatide everywhere. Telehealth companies moved in fast, compounding entered the public conversation, research peptide companies expanded and entrepreneurs followed. In most people’s minds, all of it became “the peptide market.”
The regulatory environment around compounded GLP-1s has since changed substantially. FDA says compounded drugs are not FDA-approved, meaning FDA does not review them for safety, effectiveness or quality before marketing in the same way it reviews approved drugs. In March 2026, FDA announced warning letters to 30 telehealth companies over allegedly false or misleading claims concerning compounded GLP-1 products.
FDA has kept changing the compounding framework. In April 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after concluding it had not identified a clinical need for outsourcing facilities to compound them from bulk substances.
For an entrepreneur, that proposal matters beyond GLP-1s.
A business built around healthcare cannot assume today’s drug-access environment will stay as it is.
The rules are part of the business plan.
This Doesn’t Make Telehealth a Bad Business
We think this is where serious operators separate themselves from opportunity chasers.
An opportunity chaser asks “what’s the easiest thing I can sell right now?” An operator asks “what infrastructure would I be comfortable owning if this market matures?”
Built properly, telehealth can be a substantial business. You can create a recognizable healthcare brand, build patient relationships, clinical infrastructure, technology, acquisition systems and pharmacy relationships, and possibly expand into other services. The company can grow well beyond a single medication.
The valuable telehealth company is a healthcare platform, and the website selling GLP-1 is only its front door. The valuable research peptide company is a product, distribution and brand platform, and the website selling vials is one part of it.
Both become more interesting when you stop defining them by the thing sitting on the product page.
The Marketing Is Different
This is an area where new founders can make expensive assumptions.
In telehealth, you’re marketing healthcare services and potentially prescription-drug access. FDA has been scrutinizing how telehealth companies describe compounded products. Among other things, it has warned against misleadingly presenting compounded products as equivalent to FDA-approved drugs, or implying that compounded drugs are themselves FDA-approved.
Research-product marketing has a different problem. The business must avoid telling an intended-use story that conflicts with the research model.
Across health-related advertising generally, the FTC evaluates both express and implied claims and considers the overall “net impression” an advertisement creates. Objective health claims require appropriate substantiation.
This pushes good marketers to compete on something other than ever more aggressive health promises: brand, trust, transparency, service, education, customer experience, commercial positioning, product selection and authority. Those advantages last longer anyway.
So Which Business Would We Build?
Our own experience shapes our answer here. We built Retabionix as a peptide product business. It generated approximately $500,000 in its first 45 days and today does approximately $500,000 per month across B2B and B2C revenue.
Revenue is only part of why we like the model. We like what sits underneath it: a brand, products, supply relationships, infrastructure, customers, transaction data, B2B relationships, multiple routes to market, operational knowledge, and an asset capable of becoming more valuable as those things accumulate.
We understand this kind of business because we run one. The full story is in the Retabionix case study.
It’s also why PeptiCEOs focuses on helping entrepreneurs build their own peptide brands instead of treating every opportunity in the peptide economy as the same.
Ask a Better Question Than “How Do I Get Into Peptides?”
If we were sitting across the table from someone considering this industry, we would ask them to settle “what kind of company do I want to own?” before “how do I get into peptides?”
- Do you want to coordinate clinical care?
- Do you want to build a product brand?
- Do you want B2B relationships?
- Do you want direct-to-consumer ecommerce?
- Do you have healthcare experience?
- Do you have ecommerce experience?
- How much operational complexity do you want?
- Where do you believe your competitive advantage can come from?
- What do you want the company to look like three years from now?
Those questions lead to better decisions than asking which peptide is trending this month. Trends change, and a good business should outlast the one that brought you into the market.
If the Product-Brand Model Is the One You Want
If the product-brand model is what interests you, that is the world we have spent our time in. We started PeptiCEOs because we don’t think another course is the best way to pass that experience on.
We build the business for you. Our team takes the infrastructure, relationships and operating experience we’ve developed through building and operating in this market and applies it to your own brand and business build within our scope.
You own the company, make the important decisions, and remain responsible for your business and for obtaining appropriate professional advice where required. What you skip is reverse-engineering an unfamiliar industry from YouTube videos, vendor websites and fifty open browser tabs.
Frequently Asked Questions
What is the difference between a research peptide business and a peptide telehealth business?
A research-product company is a commerce business: customer, store, product, payment, fulfillment. A telehealth company is a healthcare delivery business with a commerce layer around it: patient, intake, provider, clinical decision, prescription if medically appropriate, pharmacy, medication, ongoing care. They have different customers, revenue mechanics, infrastructure and responsibilities, even where the same molecules appear in both.
Do you need medical licences to run a peptide telehealth company?
The company coordinates the experience; licensed clinicians make clinical decisions and pharmacies dispense. But licensure still governs how far you can scale. HHS explains that the ability to deliver healthcare across state lines varies by state, and providers may need a full state licence, reciprocity, a licensure compact, a temporary-practice provision, or registration under a state telehealth pathway. Nationwide access implies substantial clinical and licensing infrastructure behind it.
Can telehealth companies still sell compounded GLP-1s?
The environment has tightened considerably. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing in the way approved drugs are. In March 2026 FDA announced warning letters to 30 telehealth companies over allegedly false or misleading claims about compounded GLP-1 products, and in April 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after finding no identified clinical need for outsourcing facilities to compound them from bulk substances.
Which is more profitable, peptide telehealth or research peptide ecommerce?
The headline revenue figure will not tell you. Two companies each doing $500,000 a month can be completely different machines: telehealth economics may include patient acquisition, provider costs, pharmacy relationships, technology and prescription workflows, while a research ecommerce business carries product costs, testing, packaging, warehousing, payment fees and fulfillment. Revenue tells you how much money passed through the front door, not what kind of house is behind it.
How do you decide which peptide business to build?
Start with the company you want to own rather than the product that is trending. Do you want to coordinate clinical care or build a product brand? Do you want B2B relationships or direct-to-consumer ecommerce? Do you have healthcare experience or ecommerce experience? How much operational complexity do you want, where do you believe your competitive advantage comes from, and what should the company look like in three years?
Sources referenced FDA, Warning Letter to Royal Peptides LLC, 24 August 2026 · FDA, Warning Letter to Gram Peptides, 31 March 2026 · FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List · HHS, Licensing across state lines · FTC, Health Products Compliance Guidance
This article reflects our operating experience and research as of September 2026. It is provided for general educational purposes and does not constitute legal, regulatory, medical or financial advice. Healthcare, pharmacy, telehealth and research-product requirements vary by product, activity and jurisdiction. Retabionix figures represent our own historical business performance and are not typical or guaranteed results.
Next step
Thinking About Building Your Own Peptide Brand?
If you’re seriously considering entering the market, we’d be happy to look at what you’re trying to build. On a Pepti Blueprint Strategy Call, we’ll look at your goals, experience, resources and the type of company you want to create. We’ll help you understand the major pieces involved, what your path could look like, and whether it makes sense for us to build it with you.
If there’s a fit, we’ll show you exactly how Pepti Blueprint works and what we’d build for you. If there isn’t, we’ll tell you that too. You can also read the whole build, step by step, before you speak to anyone.
We accept three partners per month. Applications are reviewed in the order they arrive.